According to Forbes Business Insights, skyrocketing demand for depression management amid the pandemic has driven the addressable market for mental health solutions to a whopping $35 billion.
The antidepressant market alone is projected to reach $18.29 Billion by 2027.
Early stage investors are positioned in such a way that finding and investing in the pioneers of alternative mental health products could be like investing in medicinal cannabis in 2009.
Due to side effects and consumer sentiment, there is a fast growing demand for alternatives to the typical SSRIs that are often over-prescribed and potentially dangerous for some.
If being early is the most important factor for jumping on massive trends, then it doesn't get much earlier than this.
Ei.Ventures is the first Psychedelic Medicine company in the world to qualify a Reg A Tier 2 offering.
And until March 22, 2022, you can secure your spot in what we believe may be the greatest shift for mental health that the world has ever seen.
Ei.Ventures's flagship product, Psilly, is a whole-plant, Psilocybin-based formulation in the pre-clinical phase.
And to help bring this revolutionary treatment to the world, Ei.Ventures and Mycotopia have signed an LOI (letter of intent) to explore a merger to form a company that they intend will apply to list on the NASDAQ. In simple terms: Ei.Ventures has big plans to help a lot of people suffering from anxiety and mental illness. | 
No comments:
Post a Comment